IMNN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IM

Volume

54.90K

Next Earnings

November 12th

Loading chart

IM

IMNNImunon, Inc. Common Stock

IMNN

Pay with—

Available Balance0.00

IM

Mkt Cap

$5.9M

Volume

54.90K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026IMUNON, Inc. (Nasdaq: IMNN) announced a conference call scheduled for March 31, 2026 at 11:00 a.m. EDT to discuss 2025 financial results and provide updates on its Phase 3 clinical trial (OVATION 3) for IMNN-001, a DNA-based IL-12 immunotherapy for advanced ovarian cancer treatment.GlobeNewswire Inc. · Mar 24, 2026

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference CallIMUNON announced progress in its Phase 3 OVATION 3 clinical trial for IMNN-001, a DNA-mediated immunotherapy targeting advanced ovarian cancer. The company has enrolled its first patient, implemented cost conservation measures, and introduced a 15% stock dividend to shareholders.GlobeNewswire Inc. · Aug 5, 2025

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq RulesIMUNON, a clinical-stage biotechnology company, announced a $3.25 million private placement and the potential for an additional $6.5 million from the exercise of short-term warrants. The company plans to use the proceeds for working capital and general corporate purposes.GlobeNewswire Inc. · May 23, 2025

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian CancerNovel IL-12 Immunotherapy Administered with Standard of Care as First-Line TreatmentGlobeNewswire Inc. · Jun 24, 2024

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical TrialDNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platformGlobeNewswire Inc. · Jun 5, 2024

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingLAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago from May 31st to June 4th.GlobeNewswire Inc. · May 15, 2024

IMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateConference Call Begins Today at 11:00 a.m. Eastern TimeGlobeNewswire Inc. · May 13, 2024

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 13, 2024 to discuss financial results for the first quarter ended March 31, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.GlobeNewswire Inc. · May 6, 2024

IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarterGlobeNewswire Inc. · Apr 18, 2024

IMUNON Reports Compliance with Nasdaq Listing RequirementsLAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market. Accordingly, IMUNON complies with all applicable listing standards, and its common stock will maintain its listing on the Nasdaq Capital Market under the symbol “IMNN.”GlobeNewswire Inc. · Apr 11, 2024

to start trading

IM

IMNNImunon, Inc. Common Stock

IMNN

Pay with—

Available Balance0.00

Your PositionYou don't own any IMNN yet.

Related Tickers

Earnings